Orbimed Advisors Llc Sells 11,890 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 11,890 shares of the company’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $44.60, for a total transaction of $530,294.00. Following the completion of the sale, the director directly owned 3,598,486 shares in the company, valued at $160,492,475.60. This represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Orbimed Advisors Llc also recently made the following trade(s):

• On Wednesday, November 26th, Orbimed Advisors Llc sold 1,600 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total transaction of $71,184.00.
• On Monday, November 24th, Orbimed Advisors Llc sold 94,583 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.54, for a total transaction of $4,212,726.82.

Sionna Therapeutics Stock Performance

Shares of NASDAQ SION opened at $43.79 on Friday. The company has a 50 day simple moving average of $34.45 and a two-hundred day simple moving average of $24.10. Sionna Therapeutics, Inc. has a fifty-two week low of $7.26 and a fifty-two week high of $45.00. The company has a market capitalization of $1.95 billion and a price-to-earnings ratio of -8.99.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.06.

Analyst Ratings Changes

SION has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Tuesday. Wall Street Zen cut shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Jones Trading initiated coverage on shares of Sionna Therapeutics in a research report on Monday, September 8th. They set a “buy” rating and a $46.00 price target for the company. Royal Bank Of Canada started coverage on Sionna Therapeutics in a research note on Wednesday, September 3rd. They set a “sector perform” rating and a $22.00 target price on the stock. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Sionna Therapeutics in a report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Sionna Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. purchased a new stake in Sionna Therapeutics in the third quarter worth approximately $30,000. BNP Paribas Financial Markets bought a new position in shares of Sionna Therapeutics during the 2nd quarter valued at $31,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Sionna Therapeutics during the 2nd quarter valued at $45,000. Virtus Investment Advisers LLC purchased a new position in shares of Sionna Therapeutics in the 2nd quarter worth $96,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Sionna Therapeutics in the second quarter worth $117,000.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.